- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04728347
Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021
A Phase 2a, Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Singapore, Singapore, 169608
- SingHealth Investigational Medicine Unit (IMU), Singapore General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Individuals who:
- are able to give consent
- must have completed Study ARCT-021-01
agree to comply with all study visits and procedures
Only for subjects that will receive ARCT-021 in this study:
- are healthy and medically stable
- are not planning to donate blood or plasma until 28 days after the last dose of ARCT-021.
- are willing to refrain from strenuous exercise/activity and alcohol for at least 72 hours prior to study visits and until 28 days after the last dose of ARCT-021.
- are willing to adhere to contraception requirements if sexually active and/or are of child-bearing potential
Exclusion Criteria:
Individuals who:
- are unable to comply with the study visits or procedures in Study ARCT-021-01
received placebo in the Parent Study and who are not willing to receive ARCT-021 in this study.
Only for subjects that will receive ARCT-021 in this study:
- have or will receive any of the SARS CoV-2 or another experimental coronavirus during this study.
have a diagnosis of new clinically significant abnormalities including but not limited to
- Respiratory disease requiring daily medications or oxygen currently or any treatment of respiratory disease exacerbations
- Significant heart conditions
- Significant neurological conditions
- Significant blood disorders
- Newly diagnosed autoimmune disease
- Major surgery
- have abnormal screening laboratory results
- have uncontrolled diabetes
- use of any prescription or over-the-counter medications within 7 days prior to vaccination
- have received immunoglobulins and/or any blood or blood products
- have a bleeding disorder
- have uncontrolled blood pressure
- have been treated with another investigational drug, biological agent, or device since completion of the Parent Study
have received or plan to receive:
- A licensed, live vaccine within 4 weeks before or after study vaccination, or
- A licensed, inactivated vaccine within 2 weeks before or after study vaccination
- have traveled outside of Singapore within 30 days before the vaccination or plans to travel outside of Singapore within 60 days after vaccination.
- other restrictions may apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: ARCT-021
Participants will receive a single dose of ARCT-021 on Day 1
|
ARCT-021 single dose
|
NO_INTERVENTION: Long-term follow up from ARCT-021-01
Participants will not receive intervention but will be followed for safety.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentages of participants reporting solicited local adverse events
Time Frame: for 7 days following last study vaccine dose administration
|
Adverse events reported daily in a diary that reflect common symptoms or findings at the injection site following vaccination
|
for 7 days following last study vaccine dose administration
|
Percentages of participants reporting solicited systemic adverse events
Time Frame: for 7 days following last study vaccine dose administration
|
Adverse events reported daily in a diary that reflect generalized symptoms following vaccination
|
for 7 days following last study vaccine dose administration
|
Percentages of participants reporting adverse events
Time Frame: for 28 days following last study vaccine dose administration
|
Spontaneously reported adverse events
|
for 28 days following last study vaccine dose administration
|
Percentages of participants reporting serious adverse events
Time Frame: for 12 months following last study vaccine dose administration
|
Unsolicited adverse events that meet the definition of serious
|
for 12 months following last study vaccine dose administration
|
Percentages of participants reporting medically attended adverse events
Time Frame: for 12 months following last study vaccine dose administration
|
Unsolicited adverse events that lead to healthcare provider visit
|
for 12 months following last study vaccine dose administration
|
Percentages of participants reporting new onset of chronic disease
Time Frame: for 12 months following last study vaccine dose administration
|
Unsolicited adverse events associated with new diagnosis of chronic disease
|
for 12 months following last study vaccine dose administration
|
Percentages of participants with abnormal safety laboratory test values
Time Frame: for 28 days following last study vaccine dose administration
|
Chemistry and hematology
|
for 28 days following last study vaccine dose administration
|
Percentages of participants with abnormal vital sign assessments
Time Frame: for 12 months following last study vaccine dose administration
|
Blood pressure, heart rate, respiratory rate
|
for 12 months following last study vaccine dose administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
SARS-CoV-2 serum neutralizing antibody levels, expressed as GMTs
Time Frame: for 12 months following last study vaccine dose administration for participants dosed in ARCT-021-02 study and for 15 months following last study vaccine dose administration for participants dose in the ARCT-021-01 study
|
Neutralizing antibody response
|
for 12 months following last study vaccine dose administration for participants dosed in ARCT-021-02 study and for 15 months following last study vaccine dose administration for participants dose in the ARCT-021-01 study
|
SARS-CoV-2 binding antibody levels, expressed as GMCs
Time Frame: for 12 months following last study vaccine dose administration for participants dosed in ARCT-021-02 study and for 15 months following last study vaccine dose administration for participants dose in the ARCT-021-01 study
|
Binding antibody response
|
for 12 months following last study vaccine dose administration for participants dosed in ARCT-021-02 study and for 15 months following last study vaccine dose administration for participants dose in the ARCT-021-01 study
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- ARCT-021-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on SARS-CoV-2
-
Argorna Pharmaceuticals Co., LTDCompleted
-
Argorna Pharmaceuticals Co., LTDCompleted
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Active, not recruiting
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological...Active, not recruiting
-
University Hospital Inselspital, BerneUniversity of Bern; Lucerne University of Applied Sciences and ArtsCompleted
-
Centre Hospitalier Universitaire DijonUnknown
-
AIM Vaccine Co., Ltd.Zhejiang Provincial Center for Disease Control and PreventionNot yet recruiting
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological...Not yet recruiting
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical CollegeActive, not recruiting
-
AIM Vaccine Co., Ltd.Hunan Provincial Center for Disease Control and PreventionCompleted
Clinical Trials on ARCT-021
-
Arcturus Therapeutics, Inc.Completed
-
Arcturus Therapeutics, Inc.RecruitingCOVID-19 | Corona Virus Infection | SARS-CoV-2 InfectionUnited States, Singapore
-
Arcturus Therapeutics, Inc.TerminatedCovid19 | Corona Virus Infection | SARS-CoV InfectionUnited States, Singapore
-
Genentech, Inc.CompletedUlcerative ColitisBelgium, Spain, New Zealand, United States, Czech Republic, Germany, Australia, United Kingdom, Israel, Hungary, Canada
-
Pharming Technologies B.V.CompletedGenetic DisordersNetherlands
-
Arcturus Therapeutics, Inc.CompletedOrnithine Transcarbamylase DeficiencyNew Zealand
-
Arcturus Therapeutics, Inc.Novotech CRORecruiting
-
Travere Therapeutics, Inc.RecruitingImmunoglobulin A NephropathyUnited States, Hong Kong
-
Arcturus Therapeutics, Inc.RecruitingOTC Deficiency | Ornithine Transcarbamylase Deficiency | OTCDSpain, Belgium, United Kingdom, Sweden
-
Arcturus Therapeutics, Inc.Active, not recruitingOrnithine Transcarbamylase DeficiencyUnited States